Product
PBI-0451
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase 2 Double-blind, Randomized Study to Evaluate the Antiviral Activity, Safety, and Efficacy of Orally Administered PBI-0451(Pomotrelvir) Compared With Placebo in Nonhospitalized Symptomatic Adults With COVID-19Status: Active (not recruiting), Estimated PCD: 2023-06-12